Research Article

Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients

Monica Khunger1☯, Pradnya Dinkar Patil2☯, Arjun Khunger2, Manshi Li3, Bo Hu3, Sagar Rakshit1, Arnab Basu4, Nathan Pennell2, James P. Stevenson2, Paul Elson3, Tanmay S. Panchabhai5, Vamsidhar Velcheti2*  

1 Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, United States of America, 2 Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States of America, 3 Department of Quantitate Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio, United States of America, 4 Department of Hematology and Oncology, University of Southern California, Los Angeles, California, United States of America, 5 Norton Thoracic Institute, St. Joseph’s Hospital and Medical Center, Phoenix, Arizona, United States of America  

☯ These authors contributed equally to this work.  
* velchev@ccf.org

Abstract

Background

The absolute neutrophil count (ANC), absolute lymphocyte count (ALC), absolute monocyte count (AMC) and neutrophil to lymphocyte ratio (NLR) are known markers of inflammation. We evaluated whether ANC, ALC, AMC and NLR, both before and after treatment with nivolumab, are indicative markers of overall survival (OS) and evaluated change in NLR as a predictive marker of response in non-small cell lung cancer (NSCLC) patients treated with nivolumab.

Methods

A total of 109 patients with advanced NSCLC treated with nivolumab were included. ANC, ALC, AMC and NLR were examined at initiation of nivolumab therapy and after two cycles. The prognostic role of ANC, ALC, AMC and NLR with OS and changes in NLR ratio were examined with Kaplan-Meier curves and proportional hazard model.

Result

Post-treatment NLR ≥ 5 after two cycles of nivolumab was associated with poor OS (median OS in NLR = <5 vs NLR = ≥5 was 29.1 (16.2–40.9) vs 24.2 (16.1–36.2) months respectively, p < 0.001). In addition NLR increased in non-responders after two cycles of nivolumab by 6.6 ± 21.8 as compared to responders (p = 0.027).
Conclusions
Post-treatment ANC, ALC and NLR are independent prognostic factors in NSCLC patients treated with nivolumab. Changes in NLR can be an early biomarker for response in NSCLC patients treated with nivolumab.

Introduction
Lung cancer is the most common cause of cancer related death in the United States and worldwide [1, 2]. An estimated 80–85% of patients with lung cancer have non-small-cell lung cancer (NSCLC). The recent success of immune checkpoint inhibitors in the ability to achieve durable responses in patients with NSCLC with a relatively well tolerated side effect profile has resulted in a paradigm shift in the treatment of patients with advanced NSCLC. Currently, two PD-1(programmed death -1) inhibitors, nivolumab and pembrolizumab and one PD-L1 (programmed death ligand -1) inhibitor, atezolizumab have been approved by the Food and Drug Administration (FDA) for treating patients with advanced NSCLC who have progressed after chemotherapy. In addition, pembrolizumab is approved in the front-line setting for advanced NSCLC patients as monotherapy (for PD-L1 expression greater than 50%) or in combination with platinum based chemotherapy (regardless of PD-L1 expression). However, the response rate to immunotherapy is quite modest and there is a lack of biomarkers to help distinguish responders from non-responders. Many studies have tried to explore the role of PD-L1 expression within the tumor as a biomarker, however these studies have noted that patients respond to PD-1/PD-L1 inhibitors despite “negative” PD-L1 expression. [3, 4] This observation was most prominent in patients with advanced squamous cell lung cancer treated with nivolumab. [4] Subsequently, several other trials have tried to explore TILs (tumor infiltrating lymphocytes), tumor mutational load and IL-8 as biomarkers, often with mixed results. [5–9]

Systemic inflammation has been linked to poor outcomes in many types of solid tumors. Inflammation has been associated with both the development and progression of cancer. [10] The presence of tumor associated neutrophils [11–13] macrophages [14, 15] and platelets [16, 17] in the tumor microenvironment have been shown to promote tumor growth and aide metastatic spread, therefore resulting in poor outcomes in a variety of malignancies. Tumor infiltrating lymphocytes, on the other hand have been associated with better outcomes in cancer patients including those with NSCLC. [18–24] Peripheral hematologic parameters such as absolute neutrophil count (ANC), absolute lymphocyte count (ALC), neutrophil to lymphocyte ratio(NLR) and absolute monocyte count (AMC) serve as surrogate markers of inflammation in the host and may be reflective of inflammation in the tumor microenvironment. While the exact relationship between tumor infiltrating cells (TILs) and circulating hematologic cells remains to be explored; a recent study by Dirican et al demonstrated a correlation between the TILs in the tissue microarrays of patients with NSCLC and NLR. [25]The study showed negative correlation between intratumoral CD3+ TILs and NLR and positive correlation between intratumoral CD5+ TILs and NLR. Further high intratumoral CD3+ and low CD5+ were associated with poor OS. Bagley et al concluded that high pre-treatment NLR was associated with poor OS in nivolumab treated NSCLC patients. [26] However ours is the first study to date exploring post-treatment changes in NLR ratio amongst responders and non-responders to establish the role of NLR as a predictive biomarker of durable clinical benefit with nivolumab.
Methods and materials

Patient selection

The study was approved by the Cleveland Clinic Institutional Review Board (IRB) and the requirement for informed consent was waived for this study by the IRB. Clinicopathologic data for all patients with advanced NSCLC treated with nivolumab between January 1, 2013 and October 31, 2016 at Cleveland Clinic was obtained by reviewing their electronic medical records. All data was organized in the REDCap™ database. We exclusively focused on patients treated with nivolumab (and not other PD-1/PD-L1 inhibitors) due to treatment practices at our institution as well as the fact the maximum data was available for nivolumab treated patients as compared to other treatments. This further helped minimize heterogeneity related to treatment with different PD-1/PD-L1 inhibitors. Data regarding patient demographics, histologic classification, tumor grade, line of treatment of nivolumab, driver mutation, complete blood count including a differential leukocyte count prior to treatment and after two cycles of nivolumab were collected. The RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 criteria were used to identify tumor response after completing two cycles of therapy with nivolumab. Fig 1 represents schema of patient inclusion criteria.

The primary exposure variables were pre-treatment and post-treatment ANC, ALC, AMC and NLR. Pre-treatment and post-treatment NLR were calculated as the ratio of pre-treatment and post-treatment ANC to ALC respectively. Fig 2 represents the timeline of the study.

Fig 1. Schema of patient inclusion criteria.
https://doi.org/10.1371/journal.pone.0197743.g001
including the pre-treatment CBC, pre-treatment CT chest, post-treatment CBC and post-treatment CT chest collection for assessment of response. Subgroup analysis were performed for the following pre-determined co-variables: sex of the patient, line of nivolumab therapy (<3rd line vs ≥ 3rd line and beyond), smoking status (current, former and never smoker), presence of a targetable oncogenic driver mutation (defined as having EGFR mutation and ALK translocation) and histology (squamous vs. adenocarcinoma). Data for tumor PD-L1 status was not available for majority of the patients and hence was not included in the analysis.

**Cut-off selection of hematological parameters.** Patients were dichotomized based on a cutoff value of NLR ≥ 5 and <5, as NLR ≥ 5 has been previously associated with inferior overall survival (OS) and progression free survival in melanoma patients treated with ipilimumab and NSCLC patients. [26, 27] Overall survival (OS) was the primary outcome, defined as the duration in months between the first dose of nivolumab and death. The secondary outcome of interest was durable clinical benefit (patients with complete response, partial response and stable disease) after two cycles of nivolumab as per RECIST v1.1.

**Statistical analysis**

Statistical analyses were performed using SAS 9.3 (Cary, NC) and Stata 14.1 (Stata, College Station, TX). A recursive partitioning algorithm was used to define the cutoffs for each of the inflammatory indices. ANC and ALC were divided into four quartiles as described previously; an elevated NLR was defined as ≥5. [26] The clinicopathological variables were summarized as appropriate descriptive statistics. Survival analysis was used to identify factors associated with poor OS and Kaplan meier curves were plotted for categories of pre-treatment and post-treatment ANC, ALC, AMC and NLR. Log-rank test was used to compare the survival curves. A multivariate proportional hazard model was also fitted to the data with the assumption of proportional hazard verified with residual plots. Patients were further divided into groups with durable clinical benefit (complete response, partial response and stable disease) and non-responders (progressive disease) based on their response per RECIST v1.1 to nivolumab after 2 cycles of therapy. The change in absolute NLR after 2 cycles of nivolumab in the two groups was studied using the Wilcoxon rank sum test. Statistical significance was established with a two-sided p-value < 0.05.
Results

A total of 109 patients with advanced NSCLC treated with nivolumab were included. Median age at diagnosis was 67 (range 45–90) years. Median OS of the included patients treated with nivolumab was 25 months. Median baseline ANC and ALC (IQR) were 5.3(3.7–6.8) and 1.07 (0.77–1.4) respectively. Fifty percent of the entire patient population had NLR <5 while the rest half had NLR ≥ 5 at baseline. All included patients had ECOG performance status of 0-II. The vast majority of the cohort (84%) consisted of current or former smokers and seventy six percent patients had non-squamous histology. Ninety one percent patients had received one prior systemic therapy and in fifty percent of the patients, nivolumab was second line of treatment after progression from front-line chemotherapy. Table 1 summarizes the baseline characteristics of all included patients.

Prognostic role of hematological parameters

The median duration of follow up was 30 months. Pre-treatment NLR ≥5 was associated with inferior OS as compared to NLR <5, however the difference was not statistically significant (median OS in months NLR <5 vs. NLR ≥5 months was 26.4(13.6–40.9) and 25.8(17.3–34.6) respectively; p = 0.1, Fig 3A). Post-treatment NLR ≥5 was statistically significantly associated with inferior OS (median OS in NLR = <5 vs. NLR = ≥5 was 29.1 (16.2–40.9) vs 24.2(16.1–36.2) months respectively, p<0.001; Fig 3B.

We performed an exploratory analysis to determine whether differences in OS and pre-and post-treatment NLR were attributable mainly to the ALC, ANC, or both. We divided both pre and post-treatment ANC and ALC cohorts into quartiles. We generated survival curves by quartile for each of these values according to the Kaplan-Meier method. Patients in the highest quartile of post-treatment ALC had superior OS compared to the rest of the population (log-rank p = 0.0113; Fig 4A). Patients in the highest quartile of post-treatment ANC had inferior OS compared to all others (log-rank p = 0.0027; Fig 4B). Patients in the highest quartile of pre-treatment ALC tended towards superior OS however the result was not statistically significant (p = 0.2975; Fig 4C). Similarly patients in the highest quartile of pre-treatment ANC tended towards inferior OS as compared to all other patients, however the results were not statistically significant (p = 0.2493; Fig 4D). No significant difference between pre-treatment and post-treatment AMC with OS were noted. (S1 Fig).

Predictive role of hematological parameters

Non-responders had an increase in NLR by 6.6±21.8, whereas patients with stable disease, partial or complete response after two cycles of nivolumab were noted to have an increase in NLR by only 0.25±8.6 and this difference was statistically significant (p = 0.037). Table 2 summarizes the mean ANC, ALC, AMC and NLR in patients with advanced NSCLC, both pre-treatment and after two cycles of nivolumab. Patients who had progressive disease after two cycles of nivolumab were found to have statistically significantly higher AMC as compared to responders. However no significant differences in the mean ANC, ALC and NLR were noted among responders and non-responders.

Multivariate Cox proportional hazards model was used to determine whether pre and post treatment ANC, ALC, AMC and NLR and/or other baseline characteristics were associated with OS. Post treatment ANC and ALC were significantly associated with OS using the multivariate Cox proportional hazards model. High Post treatment ANC ≥5.10 as compared to patients with ANC <5.10 was associated with inferior OS (HR = 4.7, 95% CI, 1.5–15.1; p = 0.0087). On the contrary, high post treatment ALC ≥0.77 was associated with superior OS as compared to patients with low post-treatment ALC (HR = 0.36, 95% CI, 0.15–0.86;
Table 1. Baseline characteristics of all included patients.

| Variable                                | N (%) or Median (Range) |
|-----------------------------------------|-------------------------|
| Sex                                     |                         |
| Male                                    | 56 (51.4%)              |
| Female                                  | 53 (48.6%)              |
| Age (mean) at Start of nivolumab        | 67 (45–90)              |
| Histology                               |                         |
| Adenocarcinoma                          | 71 (65.2%)              |
| Squamous cell                           | 26 (23.8%)              |
| Other                                   | 12 (11%)                |
| Smoking History                         |                         |
| Current                                 | 14 (12.8%)              |
| Former                                  | 78 (71.6%)              |
| Never                                   | 17 (15.6%)              |
| eGFR mutation                           |                         |
| Present                                 | 10 (9%)                 |
| Absent                                  | 86 (79%)                |
| Unknown                                 | 13 (12%)                |
| ALK mutation                            |                         |
| Present                                 | 0                       |
| Absent                                  | 93 (85%)                |
| Unknown                                 | 16 (15%)                |
| Pre-treatment ANC                       |                         |
| Min—3.72                                | 28 (25.7%)              |
| 3.72–5.29                               | 27 (24.8%)              |
| 5.29–6.78                               | 27 (24.8%)              |
| 6.78—Max                                | 27 (24.8%)              |
| Pre-treatment ALC                       |                         |
| Min—0.77                                | 27 (24.8%)              |
| 0.77–1.07                               | 27 (24.8%)              |
| 1.07–1.40                               | 27 (24.8%)              |
| 1.40—Max                                | 28 (25.6%)              |
| Pre NLR                                 |                         |
| <5                                      | 54 (49.5%)              |
| ≥5                                      | 55 (50.5%)              |
| Post NLR                                |                         |
| <5                                      | 58 (53.2%)              |
| ≥5                                      | 51 (46.8%)              |
| Pre AMC                                 |                         |
| <0.5                                    | 26 (23.9%)              |
| 0.5–0.8                                 | 40 (36.7%)              |
| ≥0.8                                    | 43 (39.4%)              |
| Median interval between diagnosis and treatment with Nivolumab | 8.5 months |
| Median OS (95% CI)                      | 25.1 (15.6–39) months  |
| Nivolumab Treatment "Line"              |                         |
| First line                              | 10 (9.2)                |
| Second line                             | 51 (46.8)               |
| Third line                              | 23 (21.1)               |
| Fourth line                             | 17 (15.6)               |

(Continued)
p = 0.02). However in the multivariate Cox proportional hazards model, no significant changes in pre or post treatment AMC were observed.

Sub-group analysis of pre-treatment as well as post-treatment NLR, ANC, AMC and ALC was performed based on tumor histology. No significant differences in the pre-treatment NLR and OS were noted in patients with squamous cell lung carcinoma (n = 26) and adenocarcinoma (n = 71; p = 0.4143 and p = 0.6980 respectively).

The median duration between diagnosis and treatment of nivolumab was 8.5 months. Among patients who were treated with nivolumab early during their disease course, defined as time duration between diagnosis and nivolumab treatment < 8.5 months (n = 54), the pre-treatment NLR was 6.6±4.4. Among patients who were treated with nivolumab ≥ 8.5 months after diagnosis (n = 54), the pre-treatment NLR was 5.7±3.9 and the difference between the two groups was not statistically significant; p = 0.26. Similarly, no significant differences between NLR were noted in patients who received nivolumab as <3rd line treatment (n = 74 patients) as compared to patients who received nivolumab as ≥3rd line of treatment (n = 25; 6.3±4.2 vs 5.6±3.7 respectively, p = 0.48).

**Discussion**

Our present study included 109 patients with advanced NSCLC treated with nivolumab and correlated pre and post treatment hematological parameters with OS. Post-treatment NLR ≥5 and high post-treatment ANC were associated with worse OS. High ALC was associated with superior OS in NSCLC patients treated with nivolumab. In addition patients with progressive disease after nivolumab treatment had a statistically significant increase in NLR as compared to patients with durable clinical benefit and the differences were statistically significant. This
Fig 4A: OS and post-treatment ALC. Highest ALC was associated with superior OS ($p = 0.0113$).

Fig 4B: OS and post-treatment ANC. Highest ANC was associated with inferior OS ($p = 0.0027$).

Fig 4C: OS and pre-treatment ALC. Highest ALC tended towards superior OS though the difference was not statistically significant ($p = 0.2975$).

Fig 4D: OS and pre-treatment ANC. Highest ANC tended towards inferior OS though the difference was not statistically significant ($p = 0.2493$).

Table 2. Summary statistics for hematological parameter among patients with objective response (CR, PR) as compared to non-responders (PD).

| Hematological parameter | Mean pre-treatment hematological parameter in responders | Mean pre-treatment hematological parameter in non-responders | P value of pre-treatment hematological parameter among responders and non-responders | Mean post-treatment hematological parameter in responders | Mean post-treatment hematological parameter in non-responders | P value of post-treatment hematological parameter among responders and non-responders |
|-------------------------|-------------------------------------------------------|----------------------------------------------------------|---------------------------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|----------------------------------------------------------------------------------|
| ANC                     | 5.4±2.5                                               | 6.3±3.3                                                   | 0.13                                                                             | 7.6±12.8                                                  | 10.3±16.0                                                 | 0.39                                                                             |
| ALC                     | 1.2±0.58                                              | 1.2±0.64                                                  | 0.77                                                                             | 1.8±2.4                                                   | 1.1±0.69                                                  | 0.070                                                                            |
| NLR                     | 6.1±4.4                                               | 6.5±3.9                                                   | 0.66                                                                             | 6.6±11.0                                                  | 13.1±22.4                                                 | 0.093                                                                            |
| AMC                     | 0.73±0.33                                             | 0.75±0.34                                                 | 0.85                                                                             | 0.63±0.24                                                 | 0.76±0.34                                                 | 0.035                                                                            |

https://doi.org/10.1371/journal.pone.0197743.t002
observation suggests that changes in NLR ratio as well as post-treatment ANC and ALC can be a potential predictive biomarker for response in NSCLC patients treated with nivolumab.

Tumor cells secrete chemokines such as IL-8 and recruit neutrophils into the tumor which in return promote angiogenesis, result in growth factor release, and aide vascular invasion, therefore increasing metastatic potential. Subsequently, numerous studies have shown that tumor associated neutrophils are associated with poor outcomes in many malignancies. [11–13] PD-1/PD-L1 inhibitors decrease anti-tumor immune tolerance and subsequently increase anti-tumor immunity by blocking negative regulators of T cells. Hence it is theoretically plausible that treatment response could produce relative alterations in the proportions of circulating neutrophils and lymphocytes and vice versa.

PD-L1 testing has its limitations and while the utility of TILs, tumor mutation burden as biomarkers is currently being explored; complete blood count and differential testing is inexpensive and routinely performed every cycle in patients treated with PD-1/PD-L1 inhibitors making NLR an inexpensive, universally accessible predictive and prognostic marker of response to therapy.

Our study had several limitations due to its retrospective study design. The presence of concurrent inflammatory states or use of immunomodulatory drugs which could have influenced the inflammatory markers could not be ruled out. It is a single center study and further prospective, multi-institution studies are warranted to investigate the utility of these markers in clinical practice.

**Conclusion**

Our study shows that an elevated NLR after two cycles of nivolumab as well as high ANC after treatment was significantly associated with worse OS in patients with advanced NSCLC. On the contrary high ALC post-treatment was associated with superior outcomes in NSCLC. An increase in NLR after two cycles was seen in patients who had disease progression. However, further multi-institutional studies are warranted to establish NLR as a prognostic biomarker and changes in NLR as a predictive marker of response to PD-1/PD-L1 inhibitors.

**Supporting information**

S1 Fig. Kaplan–Meier curve representing association of OS with pre-treatment AMC (supplementary Fig 1A) and post-treatment AMC (supplementary Fig 1B).

(TIF)

**Author Contributions**

**Conceptualization:** Monica Khunger, Pradnya Dinkar Patil, Arjun Khunger, Bo Hu, Sagar Rakshit, Arnab Basu, Nathan Pennell, James P. Stevenson, Tanmay S. Panchabhai, Vamsidhar Velcheti.

**Data curation:** Monica Khunger, Pradnya Dinkar Patil, Sagar Rakshit, Arnab Basu, Paul Elson, Tanmay S. Panchabhai, Vamsidhar Velcheti.

**Formal analysis:** Monica Khunger, Pradnya Dinkar Patil, Arjun Khunger, Manshi Li, Bo Hu, Sagar Rakshit, Paul Elson, Tanmay S. Panchabhai.

**Funding acquisition:** James P. Stevenson, Tanmay S. Panchabhai, Vamsidhar Velcheti.

**Investigation:** Monica Khunger, Pradnya Dinkar Patil, Manshi Li, Bo Hu, Sagar Rakshit, James P. Stevenson, Paul Elson, Tanmay S. Panchabhai, Vamsidhar Velcheti.
Methodology: Monica Khunger, Pradnya Dinkar Patil, Arjun Khunger, Manshi Li, Bo Hu, Sagar Rakshit, Nathan Pennell, James P. Stevenson, Paul Elson, Tanmay S. Panchabhai, Vamsidhar Velcheti.

Project administration: Nathan Pennell, James P. Stevenson, Vamsidhar Velcheti.

Resources: Pradnya Dinkar Patil, Nathan Pennell, Vamsidhar Velcheti.

Software: Monica Khunger, Pradnya Dinkar Patil, Manshi Li, Bo Hu, Paul Elson, Vamsidhar Velcheti.

Supervision: Nathan Pennell, James P. Stevenson, Vamsidhar Velcheti.

Validation: Monica Khunger, Pradnya Dinkar Patil, Bo Hu, Arnab Basu, Nathan Pennell, Paul Elson, Tanmay S. Panchabhai, Vamsidhar Velcheti.

Visualization: Monica Khunger, Pradnya Dinkar Patil, Arnab Basu, Nathan Pennell, James P. Stevenson, Tanmay S. Panchabhai, Vamsidhar Velcheti.

Writing – original draft: Monica Khunger, Pradnya Dinkar Patil, Arjun Khunger, Manshi Li, Bo Hu, Sagar Rakshit.

Writing – review & editing: Monica Khunger, Pradnya Dinkar Patil, Arjun Khunger, Manshi Li, Bo Hu, Sagar Rakshit, Arnab Basu, Nathan Pennell, James P. Stevenson, Paul Elson, Tanmay S. Panchabhai, Vamsidhar Velcheti.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: a cancer journal for clinicians. 2015; 65(1):5–29.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011; 61(2):69–90.
3. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. New England Journal of Medicine. 2015; 373(17):1627–39. https://doi.org/10.1056/NEJMoa1507643 PMID: 26412456
4. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. New England Journal of Medicine. 2015; 373(2):123–35. https://doi.org/10.1056/NEJMoa1504627 PMID: 26028407
5. Goodman AM, Kato S, BazhenoVa L, Patel SP, Frampton GM, Miller V, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Molecular cancer therapeutics. 2017:molcanther. 0386.2017.
6. Yuan J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen TO, et al. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. Journal for immunotherapy of cancer. 2016; 4(1):3.
7. Vareki SM, Garrigós C, Duran I. Biomarkers of response to PD-1/PD-L1 inhibition. Critical reviews in oncology/hematology. 2017; 116:116–24. https://doi.org/10.1016/j.critrevonc.2017.06.001 PMID: 2893793
8. Remon J, Chaput N, Planchard D. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer. Current opinion in oncology. 2016; 28(2):122–8. https://doi.org/10.1097/CCQ.0000000000000263 PMID: 26756384
9. Sanmamed M, Perez-Gracia J, Schalper K, Fusco J, Gonzalez A, Rodriguez-Ruiz M, et al. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Annals of Oncology. 2017; 28(8):1988–95. https://doi.org/10.1093/annonc/mdx190 PMID: 28595336
10. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454(7205):436–44. https://doi.org/10.1038/nature07205 PMID: 18650914
11. Moses K, Brandau S, editors. Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells. Seminars in immunology; 2016: Elsevier.
12. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nature medicine. 2015; 21(8):938–45. https://doi.org/10.1038/nm.3909 PMID: 26193342

13. Hagerling C, Web Z, editors. Neutrophils: Critical components in experimental animal models of cancer. Seminars in immunology; 2016: Elsevier.

14. Lim SY, Yuzhalin AE, Gordon-Weeks AN, Muschel RJ. Tumor-infiltrating monocytes/macrophages promote tumor invasion and migration by upregulating S100A8 and S100A9 expression in cancer cells. Oncogene. 2016.

15. Häuselmann I, Roblek M, Protsuky D, Huck V, Knoplova L, Grässle S, et al. Monocyte Induction of E-Selectin–Mediated Endothelial Activation Releases VE-Cadherin Junctions to Promote Tumor Cell Extravasation in the Metastasis Cascade. Cancer Research. 2016; 76(18):5302–12. https://doi.org/10.1158/0008-5472.CAN-16-0784 PMID: 27488527

16. Walsh TG, Metharom P, Berndt MC. The functional role of platelets in the regulation of angiogenesis. Platelets. 2015; 26(3):199–211. https://doi.org/10.3109/09537104.2014.909022 PMID: 24832135

17. Bambace N, Holmes C. The platelet contribution to cancer progression. Journal of thrombosis and haemostasis. 2011; 9(2):237–49. https://doi.org/10.1111/j.1538-7836.2010.04131.x PMID: 21040448

18. Horne ZD, Jack R, Gray ZT, Siegfried JM, Wilson DO, Yousem SA, et al. Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. Journal of Surgical Research. 2011; 171(1):1–5. https://doi.org/10.1016/j.jss.2011.03.068 PMID: 21571304

19. Zeng D Q, Yu Y F, Ou Q Y, Li X Y, Zhong R Z, Xie C M, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer. Oncotarget. 2016; 7(12):13765. https://doi.org/10.18632/oncotarget.7282 PMID: 26871598

20. Feng W, Li Y, Shen L, Cai X-W, Zhu Z-F, Chang J-H, et al. Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA (N2) non-small cell lung cancer. Oncotarget. 2016; 7(6):7227. https://doi.org/10.18632/oncotarget.6979 PMID: 26811495

21. Nguyen N, Bellile E, Thomas D, McHugh J, Rozek L, Virani S, et al. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head & neck. 2016.

22. Carbognin L, Pilotto S, Nortilli R, Brunelli M, Nottegar A, Sperduti I, et al. Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting. The oncologist. 2016; 21(3):283–91. https://doi.org/10.1634/theoncologist.2015-0307 PMID: 26865589

23. Kang B, Seo A, Yoon S, Bae H, Jeon S, Kwon O, et al. Prognostic value of tumor-infiltrating lymphocytes in Epstein–Barr virus-associated gastric cancer. Annals of Oncology. 2016; 27(3):494–501. https://doi.org/10.1093/annonc/mdv610 PMID: 26673353

24. Gilbert DC, Serup-Hansen E, Linnemann D, Hög dall E, Bailey C, Summers J, et al. Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer. British journal of cancer. 2016; 114(2):134–7. https://doi.org/10.1038/bjc.2015.448 PMID: 26730577

25. Dirican N, Karakaya YA, Gunes S, Daloglu FT, Dirican A. Association of Intratumoral Tumor Infiltrating Lymphocytes and Neutrophil-to-Lymphocyte Ratio Are an Independent Prognostic Factor in Non-Small Cell Lung Cancer. The clinical respiratory journal. 2015. Epub 2015/12/01. https://doi.org/10.1111/crj.12417

26. Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer. 2017; 106:1–7. https://doi.org/10.1016/j.lungcan.2017.01.013 PMID: 28285682

27. Ferrucci P, Gandini S, Battaglia A, Alfieri S, Di Giacomo A, Giannarelli D, et al. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. British journal of cancer. 2015; 112(12):1904. https://doi.org/10.1038/bjc.2015.180 PMID: 26010413